title: Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study.
authors.forename: M L
authors.initials: ML
authors.lastname: Devine
authors.forename: G J
authors.initials: GJ
authors.lastname: Dow
authors.forename: B R
authors.initials: BR
authors.lastname: Greenberg
authors.forename: D W
authors.initials: DW
authors.lastname: Holstein
authors.forename: L
authors.initials: L
authors.lastname: Icaza
authors.forename: P Y
authors.initials: PY
authors.lastname: Jue
authors.forename: F H
authors.initials: FH
authors.lastname: Meyers
authors.forename: E
authors.initials: E
authors.lastname: O'Brien
authors.forename: C M
authors.initials: CM
authors.lastname: Roberts
authors.forename: G L
authors.initials: GL
authors.lastname: Rocchio
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D013759:Dronabinol / Q000009:adverse effects*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D013759:Dronabinol